The adjuvant treatment revolution for high-risk melanoma patients.

The adjuvant treatment revolution for high-risk melanoma patients.

Publication date: Aug 21, 2019

The past 5 years have witnessed the results of many practice-changing studies that have dramatically improved the landscape of adjuvant therapy in patients with resected, high-risk melanoma. After a 20-year era of adjuvant interferon, the anti-CTLA-4 and anti-PD-1 immune-checkpoint inhibitors, and MAPK-directed targeted therapy brought a revolution into the adjuvant treatment of melanoma. These results came along with the practice-changing results of two large multicenter studies showing no benefit in terms of overall survival for completion lymph node dissection after positive sentinel node biopsy. In this review, we summarized the current state of the art of the adjuvant treatment of high-risk melanoma, with a view on future perspectives.

Spagnolo, F., Boutros, A., Tanda, E., and Queirolo, P. The adjuvant treatment revolution for high-risk melanoma patients. 23882. 2019 Semin Cancer Biol.

Concepts Keywords
Adjuvant Adjuvant immunotherapy Melanoma
Adjuvant Therapy Immunotherapy
Interferon Adjuvant therapy
Lymph Node Dissection Medicine
MAPK Clinical medicine
Melanoma Cancer treatments
Sentinel Node Biopsy Adjuvant therapy
Targeted Therapy Melanoma
Checkpoint inhibitor
Neoadjuvant therapy

Semantics

Type Source Name
gene UNIPROT AGRP
gene UNIPROT LARGE1
gene UNIPROT RPL17
gene UNIPROT CTLA4
gene UNIPROT EHD1
pathway BSID Melanoma
disease DOID melanoma
disease MESH melanoma

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *